Approval · Notice of Compliance 24193 · 2020
TARO-SUMATRIPTAN: Notice of Compliance 24193
Issued September 9, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24193
- Date
- September 9, 2020
- Company
- Taro Pharmaceuticals IncBrampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Change in drug manufacturing process
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TARO-SUMATRIPTAN | Not yet assigned | — |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 6 MG per 0.5ML